January 2025 US Undervalued Small Caps With Insider Action To Consider

In This Article:

Over the last 7 days, the United States market has risen by 2.4%, contributing to a remarkable 25% climb over the past year, with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying small-cap stocks that are currently undervalued and exhibit insider activity can present intriguing opportunities for investors seeking potential growth.

Top 10 Undervalued Small Caps With Insider Buying In The United States

Name

PE

PS

Discount to Fair Value

Value Rating

OptimizeRx

NA

1.1x

44.15%

★★★★★☆

Quanex Building Products

33.3x

0.9x

38.67%

★★★★☆☆

First United

13.0x

3.0x

47.13%

★★★★☆☆

Franklin Financial Services

10.4x

2.0x

33.90%

★★★★☆☆

McEwen Mining

4.3x

2.2x

44.35%

★★★★☆☆

Innovex International

9.2x

2.1x

47.28%

★★★★☆☆

ChromaDex

305.2x

4.9x

29.74%

★★★☆☆☆

ProPetro Holding

NA

0.8x

11.49%

★★★☆☆☆

Delek US Holdings

NA

0.1x

-75.07%

★★★☆☆☆

Sabre

NA

0.4x

-64.39%

★★★☆☆☆

Click here to see the full list of 45 stocks from our Undervalued US Small Caps With Insider Buying screener.

Let's explore several standout options from the results in the screener.

ChromaDex

Simply Wall St Value Rating: ★★★☆☆☆

Overview: ChromaDex is a bioscience company focused on developing and commercializing dietary supplements and ingredients, with a market cap of $0.19 billion.

Operations: ChromaDex's revenue is primarily derived from consumer products, followed by ingredients and analytical reference standards and services. The company's gross profit margin has shown an upward trend, reaching 61.45% in the latest period. Operating expenses are a significant cost component, with general and administrative expenses being the largest contributor.

PE: 305.2x

ChromaDex, a smaller player in the U.S. market, is gaining attention for its innovative health products like Niagen IV, now available nationwide. Despite a volatile share price recently, their financials show promise with Q3 2024 sales hitting US$25.58 million, up from US$19.5 million the previous year. Insider confidence is evident as individuals within the company have been purchasing shares over recent months, signaling potential growth optimism amidst projected revenue increases and expanding product lines.

NasdaqCM:CDXC Share price vs Value as at Jan 2025
NasdaqCM:CDXC Share price vs Value as at Jan 2025

SNDL

Simply Wall St Value Rating: ★★★☆☆☆

Overview: SNDL is a company engaged in liquor retail, cannabis retail, and cannabis operations with a market capitalization of CA$1.09 billion.

Operations: The company generates revenue primarily through liquor retail, cannabis retail, and cannabis operations. The gross profit margin has shown an upward trend, reaching 25.12% as of the latest reporting period.